Healwell AI Approaches Pivotal Earnings Release

Healwell AI reports full-year 2025 results March 19, 2026. Review commercial deals, scientific progress, and Q3 revenue of $30.4M ahead of the release.

The coming week represents a significant milestone for Healwell AI Inc. The Canadian healthcare artificial intelligence company is scheduled to release its full-year 2025 financial results on March 19, 2026. Market anticipation has been building, fueled by a series of operational and scientific advancements reported by the firm in recent weeks.

Commercial Momentum and Global Footprint

On the commercial front, Healwell has secured several key contracts. Early March saw the company sign a multi-year, multi-million dollar software agreement with a U.S.-based Health Information Exchange (HIE). This deal, secured through its subsidiaries Orion Health and VeroSource, will facilitate secure data aggregation for millions of patients across an entire American state.

The company's international presence is also expanding. Healwell announced its first contractually secured AI implementation in the Middle East in late February, alongside the expansion of active deployments in Canada and the United States. Furthermore, February marked the launch of the WELLTRUST™ platform, a privacy-compliant patient identification system for clinical trials developed in partnership with WELL Health. The system is now operational within WELL-managed clinics across Canada.

Strengthening Scientific Credibility

The scientific foundation supporting Healwell's DARWEN™ AI platform continues to solidify. On March 12, 2026, the company announced that additional research papers had been accepted for presentation at international scientific conferences, including the congress of the European Crohn's and Colitis Organisation. This brings the platform's total peer-reviewed publications to 47, spanning multiple disease areas and diverse patient populations.

The 2026 studies cover a broad clinical spectrum: treatment patterns in inflammatory bowel disease, AI-assisted clinical decision support for Type 2 diabetes, and suicidal ideation among psoriasis patients undergoing systemic therapy. One notable study, conducted with the U.S. subsidiary of a major pharmaceutical company, demonstrates how AI-enriched data from Canadian patient programs can generate real-world evidence applicable to the U.S. market.

Financial Performance and Market Context

Investors will be closely comparing the upcoming annual figures to the company's most recent quarterly disclosure. For the third quarter of 2025, Healwell reported revenue from continuing operations of $30.4 million, which annualizes to approximately $120 million. Its adjusted EBITDA showed a profit of $0.7 million, a notable improvement from a $2.8 million loss in the same quarter the previous year. The net loss from continuing operations for Q3 2025 was $16 million.

The equity's current trading price remains roughly 50% below its 52-week high from March 2025. However, shares have staged a significant recovery from their low point in February 2026. The full-year results on March 19 and the subsequent conference call scheduled for March 20 are expected to reveal whether the recent operational momentum is reflected in the annual financial statements. Management's commentary detailing the concrete path to sustained profitability will likely be a key focus for the market.